The license enables Bionova to integrate the Clean Genome strain into its pDNA production workflows to support client programs.

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

Dr. Stacy Lindborg is president and CEO of IMUNON, a clinical-stage company in phase 3 development with a lead DNA-mediated immunotherapy for advanced ovarian cancer. Dr. Lindborg has worked in the ...

Greetings, and welcome to Azenta Q1 2020 Financial Results. [Operator Instructions] As a reminder, this conference is being recorded, Wednesday, February 4, 2026. I will now turn the conference over ...

Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing ...

UVA Health scientists are reporting promising success as they pioneer a new way to create vaccines far more quickly, nimbly ...

Elegen sets a new benchmark for clonal, cell-free synthetic DNA with ENFINIA, delivering unmatched length and accuracy from ...

In this second of three articles on The Sunday Times top 100 tech companies list, pharmaphorum is focusing on the first nine ...

The Seattle facility of AGC Biologics, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from Agência Nacional de Vigilância Sanitária (Anvisa), Brazil's health ...

RelPro, a fast-growing business development solution for Financial & Professional Services and B2B data platform, today announced the appointment of Raaj Rajmangal as Chief Executive Officer as the ...

Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.

Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2025 results on Jan. 29, before market open. In the last reported quarter, earnings of $5.79 per share beat the Zacks Consensus ...